A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.
Breakthrough £90,000 Alzheimer’s drugs unlikely to benefit patients, report suggests
A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.